Our 2005 development programs are primarily designed to support additional uses of XIFAXAN(TM), develop granulated mesalamine for the maintenance of remission of ulcerative colitis, and to progress life cycle management programs for COLAZAL(R) and XIFAXAN.

All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional.